Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

GlobeNewswire 10 days ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

GlobeNewswire May 8, 2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2024

Kura Oncology Reports First Quarter 2024 Financial Results

GlobeNewswire May 2, 2024

Kura Oncology to Report First Quarter 2024 Financial Results

GlobeNewswire April 25, 2024

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

GlobeNewswire April 22, 2024

Kura Oncology to Participate in Stifel Targeted Oncology Forum

GlobeNewswire April 10, 2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

GlobeNewswire March 6, 2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 1, 2024

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 27, 2024

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

GlobeNewswire February 26, 2024

Kura Oncology to Participate in Three Upcoming Investor Conferences

GlobeNewswire February 22, 2024

Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 20, 2024

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2024

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

GlobeNewswire January 30, 2024

Kura Oncology Announces Oversubscribed $150 Million Private Placement

GlobeNewswire January 24, 2024

Kura Oncology's Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society's Pediatric Acute Leukemia (PedAL) Master Clinical Trial

GlobeNewswire December 8, 2023

Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire November 28, 2023

Kura Oncology Reports Third Quarter 2023 Financial Results

GlobeNewswire November 2, 2023